Proteolytic Enzymes and Cancer
Systemic Enzyme Therapy In Cancer Patients
- has been subjected to
- experimental investigations
- rigorous clinical studies
- results of in vitro and in vivo investigations of proteolytic enzyme mixtures (trypsin, chymotrypsin, and papain or bromelain) → increase in these kinds of activity:
- immunological
- anti-inflammatory
- anti-infectious
- antitumor/antimetastatic
- results of EBM level II clinical studies in patients suffering from breast and colorectal cancers and plasmacytoma
- significantly decreases tumor-induced and therapy-induced side effects (nausea, gastrointestinal complaints, fatigue, weight loss, and restlessness)
- stabilizes the quality of life
- results for plasmacytoma patients
- increases the response rates
- increases duration of remissions
- increases the overall survival times
- results of previous studies of treatment of human white blood cells with proteolytic enzymes
- production of large amounts of tumor necrosis factor in a time and dose dependent manner
References
- Barron, J (2014, July 21). Systemic, Proteolytic Enzymes. Baseline Of Health Foundation. Retrieved from https://jonbarron.org/article/proteolytic-enzyme-formula
